HappeningToo topic
Pembrolizumab reports
Browse community reports connected to Pembrolizumab. These reports can show that other people are describing similar experiences, but they do not prove that Pembrolizumab caused a symptom or reaction.
⚕️ Medicine safety note
Community reports do not prove causation, cannot be used to estimate how common a reaction is, and are not medical advice.
25 problems
Abdominal Pain while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and abdominal pain appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Alopecia while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and alopecia appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Back Pain while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and back pain appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Constipation while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and constipation appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Cough while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and cough appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Decreased Appetite while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and decreased appetite appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Dehydration while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and dehydration appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Diarrhea while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and diarrhea appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Dizziness while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and dizziness appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Fatigue while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and fatigue appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Headache while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and headache appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Hypotension while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and hypotension appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Itching while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and itching appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Malaise while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and malaise appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Muscular Weakness while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and muscular weakness appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Myalgia while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and myalgia appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Nausea while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and nausea appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Pain while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and pain appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Peripheral swelling while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and peripheral swelling appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Rash while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and rash appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Shortness of breath while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and shortness of breath appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Skin redness while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and skin redness appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Vomiting while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and vomiting appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Weakness while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and weakness appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Weight Decreased while using Pembrolizumab
FDA FAERS contains adverse-event reports in which Pembrolizumab and weight decreased appear together. This does not establish that Pembrolizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →